ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Integrative in silico and clinical validation of urinary lncRNAs (SNHG7 & LINC00675) and β-catenin mRNA as molecular markers for early bladder cancer detection.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer (BC) is a prevalent malignancy worldwide with a higher propensity for recurrence and progression despite advancements in clinical treatment. The low sensitivity of urine cytology in detecting low-grade tumors underscores the need for reliable urinary biomarkers for early detection of BC with high sensitivity and specificity.
methodsThis study assessed the diagnostic potential of urinary long non-coding RNAs (lncRNAs), specifically small nucleolar RNA host gene 7 (SNHG7) and long intergenic non-coding RNA 00675 (LINC00675), along with β-catenin mRNA (CTNNB1). Bioinformatic analysis identified differential expression of these targets, which were clinically validated using real-time PCR in a case-control study. Our cohort comprised 97 subjects, divided into three groups: healthy controls (n = 25), benign cases (n = 20), and malignant BC cases (n = 52).
resultsThe case-control study revealed significant upregulation of SNHG7 and CTNNB1, and significant downregulation of LINC00675 in the BC group compared to the benign and healthy control groups. The sensitivity and specificity of SNHG7, LINC00675, and CTNNB1 were 80.8%, 90.4%, and 73.1%, and 86.7%, 80%, and 75.6%, respectively.Correlation analysis revealed a strong positive correlation between CTNNB1 and SNHG7 in BC (r = 0.77, p < 0.001), while an inverse trend with LINC00675.
conclusionOur findings indicate that SNHG7 and LINC00675 lncRNAs may regulate β-catenin mRNA expression, highlighting their potential as diagnostic biomarkers for bladder cancer. These results emphasize the necessity of further research to validate the diagnostic utility of these lncRNAs in bladder cancer management.
Indexed as
Identifiers
42165927What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.